Evidence map›Paper›PMID 39347716›Full record

SynthesisOncotarget2024

Zika virus and brain cancer: Can Zika be an effective treatment for brain cancer? A systematic review.

Mateus Gonçalves de Sena Barbosa, Beatriz Rodrigues Messias, Rafael Trindade Tatit, Maycon Cristian Gomes de Paula, Valdecir Boeno Spenazato Júnior, Maria Gabriella Borges Braga, Caio Vinícius Marcolino Santos, Luiza D'Ottaviano Cobos, Vinícius Otávio da Silva, Eberval Gadelha Figueiredo and 2 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Oncotarget, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mateus Gonçalves de Sena BarbosaDepartment of Neurosurgery, Atenas University Center, Passos, Minas Gerais, Brazil.
Beatriz Rodrigues MessiasHospital Israelita Albert Einstein, University of Israelita de Ciências da Saúde Albert Einstein, São Paulo, Brazil.
Rafael Trindade TatitHospital Israelita Albert Einstein, University of Israelita de Ciências da Saúde Albert Einstein, São Paulo, Brazil.
Maycon Cristian Gomes de PaulaDepartment of Neurosurgery, University of Sapucaí Valley, Pouso Alegre, Minas Gerais, Brazil.
Valdecir Boeno Spenazato JúniorDepartment of Neurosurgery, University of Sapucaí Valley, Pouso Alegre, Minas Gerais, Brazil.
Maria Gabriella Borges BragaDepartment of Neurosurgery, Atenas University Center, Sete Lagoas, Minas Gerais, Brazil.
Caio Vinícius Marcolino SantosDepartment of Neurosurgery, Nove de Julho University, Campus Vergueiro, São Paulo, Brazil.
Luiza D'Ottaviano CobosDepartment of Neurosurgery, José do Rosário Vellano University, Alfenas, Minas Gerais, Brazil.
Vinícius Otávio da SilvaDepartment of Neurosurgery, Atenas University Center, Passos, Minas Gerais, Brazil.
Eberval Gadelha FigueiredoDivision of Neurosurgery, School of Medicine-University of São Paulo (FMUSP), Hospital das Clínicas/FMUSP, São Paulo, Brazil.
Nicollas Nunes RabeloDivision of Neurosurgery, School of Medicine-University of São Paulo (FMUSP), Hospital das Clínicas/FMUSP, São Paulo, Brazil.
Bipin ChaurasiaDepartment of Neurosurgery, Neurosurgery Clinic, Birgunj, Nepal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMany studies have highlighted the use of oncolytic viruses as a new class of therapeutic agents for central nervous system (CNS) tumors, especially glioblastomas (GMB). Zika Virus (ZIKV) proteins targeted to specific stem cells have been studied MATERIALS AND

methodsA systematic review was evaluated the efficacy and safety of the ZIKV use for CNS tumors treatment. Data were extracted and the

resultsThe 14 included studies shown that ZIKV reduced cell viability or inhibited the growth, proliferation of glioma stem cells (GSCs), and Bcl2 expression - which could potentially enhance the effect of chemotherapy/radiotherapy; caused cytopathic effects, induced tumor cell damage, manifested oncolytic properties, and even selectively safely killed GSCs; ultimately, it led to significant tumor remission and enhanced long-term survival through enhanced T-cell response.

conclusionsAlthough current evidence suggests ZIKV as a promising treatment for CNS tumors and may improve survival when combined with surgery and radiotherapy. Despite limited human evidence, it shows potential benefits. Further research is needed to confirm safety, efficacy, and optimize treatment in humans.

Indexed as

Brain NeoplasmsOncolytic VirotherapyZika VirusAnimalsCell ProliferationGlioblastomaHumansNeoplastic Stem CellsOncolytic Virusesbrain tumorglioblastomagliomaneurotropismZika

Identifiers

PMID39347716
PMCPMC11441410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.